Keith Regnante - 24 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Signature
/s/ Keith Regnante
Issuer symbol
KROS
Transactions as of
24 Feb 2026
Net transactions value
$0
Form type
4
Filing time
26 Feb 2026, 16:15:23 UTC
Previous filing
20 Feb 2026

Sponsored

Quoteable Key Fact

"Keith Regnante filed Form 4 for Keros Therapeutics, Inc. (KROS) on 26 Feb 2026."

Quick Takeaways

  • This page summarizes Keith Regnante's Form 4 filing for Keros Therapeutics, Inc. (KROS).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 26 Feb 2026, 16:15.

What Changed

  • Previous filing in this sequence was filed on 20 Feb 2026.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Regnante Keith CHIEF FINANCIAL OFFICER C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Keith Regnante 26 Feb 2026 0001682068

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (Right to Buy) Award $0 +60,000 $0.000000 60,000 24 Feb 2026 Common Stock 60,000 $15.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.